Menu
FDA Grants Emergency Use of Pemgarda for Preexposure Prophylaxis of COVID-19
The Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Pemgarda™ (pemivibart), a long-acting monoclonal antibody, for the preexposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg. The treatment is authorized for patients who are not currently infected with SARS-CoV-2 and have not had a known recent exposure to an individual infected with SARS-CoV-2; and who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Full Access: FDA
5 Foolproof Strategies for Dealing with Difficult Patients
Every specialty has its fair share of challenging patients. If you aren’t mindful of how you approach these encounters, they can lead to excess worry, burnout, and the perpetual landmine of fiery google reviews. Here are a few go-to techniques for handling these interactions. Full Access: Doximity
Infections From Nontuberculous Mycobacteria Are on The Rise: New Blood Test Cuts Diagnosis Time from Months to Hours
Inhaling nontuberculous mycobacteria is common for most people. The bacteria are found in water systems, soil and dust worldwide and, for many, cause no harm. In a new study, Tulane University researchers have developed a CRISPR-based platform for diagnosing NTM infections where blood testing can yield results in as little as two hours. Full Access: ATS
As Spring Arrives, Watch Out for Oral Allergy Syndrome
Also known as food-pollen syndrome, OAS is a condition in which individuals experience symptoms to certain fresh or raw fruits, vegetables and nuts. These symptoms include itchy mouth or tongue, rash or hives around the mouth, or upset stomachs. Full Access: Helio